Regeneron Pharmaceuticals, Inc. (REGN) is a leading American biotechnology company headquartered in Tarrytown, New York. Valued at $52.9 billion by market cap, the company focuses on discovering, developing, manufacturing, and commercializing medicines for serious diseases.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and REGN perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. Its market leadership lies in its cutting-edge proprietary technologies like VelociSuite®, which enable rapid development of innovative antibody therapies. It boasts a strong and diverse product portfolio, including blockbuster drugs such as Eylea® and Dupixent®, driving consistent revenue growth.

Despite its notable strength, REGN slipped 59.5% from its 52-week high of $1,211.20, achieved on Aug. 27, 2024. Over the past three months, REGN stock declined 29.8%, compared to the Health Care Select Sector SPDR Fund’s (XLV) 10.9% decline during the same time frame.

In the longer term, shares of REGN dipped 31.1% on a YTD basis and declined 49.9% over the past 52 weeks, underperforming XLV’s YTD dip of 3.5% and 7.6% plunge over the last year.

REGN has been trading below its 200-day moving average since October, 2024 abut has been under its 200-day moving average since the end of September 2024. 

Regeneron shares fell over 19% on May 31, making it the biggest loser on the S&P 500 and Nasdaq 100, after its experimental COPD drug itepekimab, developed with Sanofi (SNY), failed to meet expectations in a late-stage trial.

In the competitive arena of biotechnology, Incyte Corporation (INCY) has taken the lead over REGN, which is down 5.4% on a YTD basis but has soared 13% over the past 52 weeks. 

Wall Street analysts are highly bullish on REGN’s prospects. The stock has a consensus “Strong Buy” rating from the 25 analysts covering it, and the mean price target of $786.88 suggests a potential upside of 60.3% from current price levels.